Search results
Results from the WOW.Com Content Network
In the European Union, the combination is indicated for the treatment of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms (88 lb) who do not require supplemental oxygen and who are at high increased risk of progressing to severe COVID‑19; [10] and for the prevention of COVID‑19 in people aged twelve years of age and older weighing at least 40 kilograms ...
On 16 April 2021, the FDA revoked the emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. [69]
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
The timeline of the COVID-19 pandemic lists the articles containing the chronology and epidemiology of SARS-CoV-2, [1] the virus that causes the coronavirus disease 2019 and is responsible for the COVID-19 pandemic. The first human cases of COVID-19 occurred in Wuhan, People's Republic of China, on or about 17 November 2019. [2]
The COVID-19 vaccination campaign in the United States is an ongoing mass immunization campaign for the COVID-19 pandemic in the United States.The Food and Drug Administration (FDA) first granted emergency use authorization to the Pfizer–BioNTech vaccine on December 10, 2020, [7] and mass vaccinations began four days later.
On July 22, 2020, the U.S. government placed a conditional advance-purchase order of $2 billion with Pfizer to manufacture 100 million doses of a COVID-19 vaccine, with an option for 500 million more, for use in the United States if the vaccine was shown to be safe, effective, licensed, and authorized by the Food and Drug Administration (FDA).
By late November 2019, coronavirus disease 2019 had broken out in Wuhan, China. [2]As reported in Clinical Infectious Diseases on November 30, 2020, 7,389 blood samples collected between December 13, 2019, and January 17, 2020, by the American Red Cross from normal donors in nine states (California, Connecticut, Iowa, Massachusetts, Michigan, Oregon, Rhode Island, Washington and Wisconsin ...
All RMPs for COVID‑19 vaccines will be published on the EMA's website. [136] The EMA published guidance for developers of potential COVID‑19 vaccines on the clinical evidence to include in marketing authorization applications. [137] In November 2020, the CHMP started a rolling review of the Moderna vaccine for COVID‑19 known as mRNA-1273 ...